Target intelligence / Profile preview

Ultraviolet-damaged DNA (UV-DNA) (UV-DNA)

Target
UV-DNA
Molecular classification
Nucleic acid, DNA lesion, Genomic substrate
01

Overview

Ultraviolet-damaged DNA consists of molecular lesions in the genomic structure caused by the absorption of UV photons, primarily resulting in cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4PPs) (NIH, 2023). These structural distortions interfere with essential cellular processes such as DNA replication and transcription, potentially leading to permanent mutations if the cell's repair machinery is bypassed (PubMed, 2021). The primary human defense against such damage is the nucleotide excision repair (NER) pathway, and its failure is a hallmark of diseases like Xeroderma pigmentosum and various skin cancers (StatPearls, 2023). In a therapeutic context, UV-damaged DNA is the target of exogenous repair enzymes like T4 endonuclease V and photolyases, which are delivered topically to enhance the rate of lesion removal (Journal of Investigative Dermatology, 2020). By reducing the persistence of these lesions, these treatments aim to prevent the progression of actinic keratosis to squamous cell carcinoma and mitigate the effects of photoaging.

Other names
UV-induced DNA lesionsCyclobutane pyrimidine dimersCPDs6-4 photoproducts6-4PPsDNA photolesionsSolar-damaged DNA
02

Mechanism of action

Therapeutic strategies involve the enzymatic repair of lesions through nucleotide excision repair (NER) or direct reversal by photolyases, as well as the prevention of lesion formation using UV-absorbing or reflecting agents (PubMed, 2021; NIH, 2023).

03

Biological functions

MutagenesisCell cycle arrestApoptosisTranscription inhibitionActivation of DNA damage response (DDR)
04

Disease associations

MelanomaBasal cell carcinomaSquamous cell carcinomaXeroderma pigmentosumActinic keratosisPhotoaging
05

Safety considerations

Risk of incomplete repair leading to error-prone bypassPotential for off-target effects of exogenous enzymesImmunogenicity of non-human proteins (e.g., bacterial or algal enzymes)Inadequate penetration of topical formulations
06

Interacting drugs

T4 endonuclease V (T4N5)

4 more in the full profile.

07

Biomarkers

Cyclobutane pyrimidine dimer (CPD) levels in skin biopsies6-4 photoproduct (6-4PP) quantificationgamma-H2AX focip53 mutation signatures (C to T transitions)

Beyond the preview

Go deeper on Ultraviolet-damaged DNA (UV-DNA) (UV-DNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ultraviolet-damaged DNA (UV-DNA) (UV-DNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call